Pharmaceuticals
OrbiMed leads $19m round for Sino-US drug developer
OrbiMed Asia Partners has led a $19 million Series B round of funding for InventisBio, a pharmaceutical developer based in Shanghai with operations in China and the US.
VCs back South Korean biopharma player ExoCoBio
South Korean biopharmaceutical developer ExoCoBio has raised an $11 million Series A round from investors including SBI Investment, Atinum Investment, ID Ventures, and Dt&Investment.
Korea to invest $102m in life science start-ups
The South Korean government has pledged to establish a KRW113.5 billion ($102 million) fund to support life science start-ups through related ecosystem and infrastructure investments.
TA buys stake in India's Ideal Cures
TA Associates has invested in Indian pharmaceutical product supplier Ideal Cures. Neither the size of the commitment nor the size of the GP's stake in the company were disclosed.
Japan's INCJ takes control of $87m pharma spin-out
The Innovation Network Corporation of Japan (INCJ) has teamed up with two pharmaceutical players to invest JPY10 billion ($87 million) in the creation of a biotech spin-out. INCJ will hold a 70.5% stake in the company.
Ally Bridge backs $301m Luoxin Pharma take-private
Healthcare-focused PE investor Ally Bridge Group will support the HK$2.3 billion ($301 million) management-led take-private of Hong Kong-listed Shandong Luoxin Pharmacy Group.
IFC set for $60m investment in SE Asian medical player
The International Finance Corporation (IFC), the investment arm of the World Bank, has proposed a commitment of $60 million to IDS Medical Systems, a Hong Kong-based healthcare industry supplier for Southeast Asia.
ChrysCapital set for exit in Eris Lifesciences IPO
Indian pharmaceutical company Eris Lifesciences has filed for a domestic IPO that is expected to facilitate a full exit for ChrysCapital Partners, which has been an investor since 2011.
Qiming leads $20m Series A for China biopharma developer
Qiming Venture Partners has led a $20 million Series A round of funding for Chinese drug developer Connect Biopharmaceuticals.
Deal focus: C -Bridge brings more co-investment to Ascletis
C-Bridge Capital participates in a $100 million Series B round of funding for biotechnology Ascletis alongside existing backer Goldman Sachs and a number of its LPs
China's Frontier Biotechnologies gets $43m round
Frontier Biotech, a China-based pharmaceutical company that works on HIV treatments, has received RMB300 million ($43 million) in Series C funding, led by Huaxin Century Investment Group.
C-Bridge leads $100m round for China's Ascletis
Healthcare-focused PE firm C-Bridge Capital has led a Series B round of funding worth $100 million for Ascletis, a Chinese biotechnology company that specializes in treatments for liver disease.
Everstone invests $35m in India's OmniActive Health
The Everstone Group has committed $35 million to Indian nutraceuticals ingredient supplier OmniActive Health Technologies. It is the firm’s third pharmaceuticals investment in less than a year.
Japan's AGC Asahi Glass buys PE-owned CMC Biologics
Japanese glass, ceramic and chemicals maker AGC Asahi Glass has paid JPY60 billion ($510 million) for CMC Biologics, a Denmark-based biopharmaceutical manufacturer backed by several private equity firms.
PE-backed Claris exits division to US strategic
Claris Lifesciences, an Indian drug maker with several PE backers, has agreed to exit its injectables division to US-based generic pharmaceutical developer Baxter International.
Three GPs chosen to manage Australia biomedical fund
OneVentures, Brandon Capital and BioScience Managers have been selected to manage the Australian government’s A$500 million ($375 million) Biomedical Translation Fund (BTF).
IVFA makes partial exit from India's Syngene
India Value Fund Advisors (IVFA) has made a partial exit from India-listed pharmaceuticals company Syngene International, selling an approximately 1.6% holding for INR1.9 billion ($27.7 million).
Mandarin acquires Italian pharmaceuticals maker
Europe-Asia cross-border focused PE firm Mandarin Capital Partners has committed EUR16.4 million ($17.7 million) for a majority stake in Italian pharmaceutical manufacturer Mipharm.
Deal focus: Eywa brings experienced edge to generics
Eight Roads Ventures India sees considerable strengths in Eywa to tackle the lucrative US generic pharmaceuticals market
Everstone pays $33m for Indian drug firm
The Everstone Group has bought a majority stake in Indian pharmaceutical developer Rubicon Research for INR2.2 billion ($32.9 million), providing an exit for Kotak Private Equity.
Chinese investors in $30m round for US genetic testing firm
Trustbridge Partners has led a $30 million Series B round for US-based genetic testing company Veritas Genetics.
Fidelity funds join $30m round for Singapore's Eywa
Eight Roads Ventures India and US-based F-Prime Capital - both of which are controlled by Fidelity - have joined a $30 million investment in Singapore and India-based drug manufacturer Eywa Pharma.
China's I-Bridge Capital launches Israel pharma JV
Chinese healthcare-focused VC firm I-Bridge Capital has launched a joint venture (JV) with Israeli biopharmaceutical company BioLineRx that will target cross-border penetration of Chinese markets.
Australian government launches $191m biomedical VC fund
The Australian government has seeded $250 million ($191 million) from its Medical Research Future Fund (MRFF) to a biomedical technology-focused venture investment vehicle. It will match private sector commitments, bringing the total available for deployment...